Bevacizumab pharmacogenetics in tumor treatment: Still looking for the right pieces of the puzzle

Pharmacogenomics

Volumn 12, Issue 8, 2011, Pages 1077-1080

  Bocci, Guido ^a,b   Loupakis, Fotios ^b,c  

^a UNIVERSITY OF PISA   (Italy)

^b ISTITUTO TOSCANO TUMORI   (Italy)

^c UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

bevacizumab; complement factor H; IL 8; pharmacogenetics; VEGF; VEGFR 2

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CHEMOKINE RECEPTOR CXCR2; COMPLEMENT FACTOR H; CYCLOPHOSPHAMIDE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FLUOROURACIL; FOLINIC ACID; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 8; IRINOTECAN; OXALIPLATIN; PACLITAXEL; TISSUE INHIBITOR OF METALLOPROTEINASE 3; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; BREAST CANCER; CANCER PATIENT; CANCER SURVIVAL; COLORECTAL CANCER; DRUG RESPONSE; GENETIC ASSOCIATION; GENOTYPE; HOMOZYGOSITY; HUMAN; HYPERTENSION; METASTASIS POTENTIAL; OVARY CANCER; OVERALL SURVIVAL; PHARMACOGENETICS; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TRANSLATIONAL RESEARCH; TUMOR CELL; TUMOR MICROENVIRONMENT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80051710027     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.75     Document Type: Review

References (20)

1. Loupakis F, Bocci G, Pasqualetti G et al. Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients. Curr. Cancer Drug Targets 10(1), 37-45 (2010).
2. Jain L, Vargo CA, Danesi R et al. The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol. Cancer Ther. 8(9), 2496-2508 (2009).
3. Schneider BP, Wang M, Radovich M et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J. Clin. Oncol. 26(28), 4672-4678 (2008).
4. Etienne-Grimaldi MC, Formento P, Degeorges A et al. Prospective analysis of the impact of VEGF-A gene polymorphisms on pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients. Br. J. Clin. Pharmacol. 71(6), 921-928 (2011).
5. Loupakis F, Ruzzo A, Salvatore L et al. VEGF gene polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts). Eur. J. Cancer (Suppl. 7), 357 (2009).
6. Masi G, Loupakis F, Salvatore L et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a Phase 2 trial. Lancet Oncol. 11(9), 845-852 (2010).
7. Loupakis F, Cremolini C, Fioravanti A et al. Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. Br. J. Cancer 104(8), 1262-1269 (2011).
8. Schultheis AM, Lurje G, Rhodes KE et al. Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin. Cancer Res. 14(22), 7554-7563 (2008).
9. Smerdel MP, Steffensen KD, Waldstrom M et al. The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab. Gynecol. Oncol. 118(2), 167-171 (2010).
10. Pander J, Wessels JA, Gelderblom H et al. Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer. Ann. Oncol. 22(5), 1147-1153 (2011).
11. Maitland ML, Ratain MJ, Cox NJ. Interpreting P values in pharmacogenetic studies: a call for process and perspective. J. Clin. Oncol. 25(29), 4513-4515 (2007). (Pubitemid 350035302)
12. Buyse M, Sargent DJ, Grothey A et al. Biomarkers and surrogate end points-the challenge of statistical validation. Nat. Rev. Clin. Oncol. 7(6), 309-317 (2010).
13. Schneider BP, Skaar TC, Sledge GW et al. Analysis of angiogenesis genes from paraffin-embedded breast tumor and lymph nodes. Breast Cancer Res. Treat. 96(3), 209-215 (2006).
14. Coltelli L, Allegrini G, Orlandi P et al. Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis. Pharmacogenomics 10(8), 1225-1229 (2009).
15. Pasqualetti G, Danesi R, Del Tacca M et al. Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy. Pharmacogenomics 8(1), 49-66 (2007). (Pubitemid 46157757)
16. Radovich M, Hancock BA, Kassem N et al. Resequencing of the vascular endothelial growth factor promoter reveals haplotype structure and functional diversity. Angiogenesis 13(3), 211-218 (2010).
17. Brantley MA Jr, Fang AM, King JM et al. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology 114(12), 2168-2173 (2007). (Pubitemid 350181136)
18. Nischler C, Oberkofler H, Ortner C et al. Complement factor H Y402H gene polymorphism and response to intravitreal bevacizumab in exudative age-related macular degeneration. Acta Ophthalmol. 89(4), e344-349 (2011).
19. Garcia AA, Hirte H, Fleming G et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital Phase II consortia. J. Clin. Oncol. 26(1), 76-82 (2008).
20. Kim JC, Kim SY, Cho DH et al. Novel chemosensitive single-nucleotide polymorphism markers to targeted regimens in metastatic colorectal cancer. Clin. Cancer Res. 17(5), 1200-1209 (2011).